AJOVista LLC Buys Shares of 7,700 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

AJOVista LLC bought a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) in the fourth quarter, HoldingsChannel reports. The fund bought 7,700 shares of the company’s stock, valued at approximately $84,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its position in shares of Edgewise Therapeutics by 228.6% during the third quarter. New York State Common Retirement Fund now owns 43,871 shares of the company’s stock worth $251,000 after buying an additional 30,522 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in Edgewise Therapeutics by 3.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 116,900 shares of the company’s stock worth $670,000 after acquiring an additional 3,900 shares in the last quarter. abrdn plc bought a new stake in Edgewise Therapeutics during the fourth quarter worth about $1,646,000. SG Americas Securities LLC bought a new stake in Edgewise Therapeutics during the third quarter worth about $107,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Edgewise Therapeutics by 349.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company’s stock worth $80,000 after acquiring an additional 5,704 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Edgewise Therapeutics in a report on Tuesday, April 16th. Truist Financial reiterated a “buy” rating and set a $25.00 target price on shares of Edgewise Therapeutics in a report on Wednesday, April 17th. Royal Bank of Canada upped their target price on Edgewise Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd. Finally, Piper Sandler assumed coverage on Edgewise Therapeutics in a research note on Thursday, March 7th. They issued an “overweight” rating and a $48.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $31.20.

Insider Transactions at Edgewise Therapeutics

In other news, General Counsel John R. Moore sold 1,956 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $36,987.96. Following the transaction, the general counsel now owns 3,252 shares in the company, valued at $61,495.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, General Counsel John R. Moore sold 1,956 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $36,987.96. Following the sale, the general counsel now owns 3,252 shares of the company’s stock, valued at $61,495.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Behrad Derakhshan sold 4,600 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $20.01, for a total value of $92,046.00. Following the sale, the insider now directly owns 7,020 shares in the company, valued at approximately $140,470.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,287 shares of company stock worth $852,061. Company insiders own 31.95% of the company’s stock.

Edgewise Therapeutics Trading Up 1.2 %

NASDAQ:EWTX traded up $0.23 on Friday, hitting $19.52. The company’s stock had a trading volume of 545,136 shares, compared to its average volume of 586,727. The firm has a market capitalization of $1.82 billion, a P/E ratio of -12.35 and a beta of 0.15. Edgewise Therapeutics, Inc. has a one year low of $5.12 and a one year high of $20.90. The stock has a fifty day moving average of $16.90 and a two-hundred day moving average of $12.73.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). As a group, sell-side analysts anticipate that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.